Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Myeloproliferative Disorders Drugs Market Expected to Be in 2029?

In past years, the market size for drugs treating myeloproliferative disorders has seen continuous growth. It’s expected that the market will expand from $9.47 billion in 2024 to $9.83 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.8%. The growth in the historical period is believed to be the outcome of a rising number of myeloproliferative disorder cases, advancements in disease mechanism comprehension, progress in clinical research and drug creation, enhanced diagnosis and screening techniques, as well as advocacy and increased public awareness for patients.

In the coming years, the market size for drugs treating myeloproliferative disorders is poised to experience consistent growth. The market is projected to reach $11.51 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.0%. The projected growth within the forecast period can be ascribed to factors such as aging demographics, advancements in precision medicine, arrival of new treatments, worldwide emphasis on rare diseases, and government-driven initiatives and healthcare policies. The major trends to watch out for in the foresight period are precision medicine strategies, clinical studies for experimental treatments, improved symptom management, wider application of ruxolitinib, and focus on disease biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10681&type=smp

What Are The Contributors To Demand In The Myeloproliferative Disorders Drugs Market?

Anticipated growth of the myeloproliferative disorder’s drugs market is largely attributed to the escalating occurrence of such disorders. These particular ailments represent a broad range of conditions that are characterized by the amplified growth of one or more blood cell types, making them distinct from acute leukemia. Genetic abnormalities, along with exposure to radiation, electricity, and chemicals, are some of the key drivers leading to an increase in myeloproliferative disorders, particularly among the aged population. Medications developed for myeloproliferative diseases work by obstructing the BCR-ABL protein. This is achieved by bonding with the ATP pocket located at the active site, which results in the prevention of the target protein’s downstream phosphorylation. This process plays a vital role in the therapy of myeloproliferative conditions. For example, figures from the National Institute of Health, a medical research institution based in the United States, indicate that in August 2022, chronic myelogenous leukemia had a higher prevalence in men. The data showed about 2.4 new cases per 100,000 in contrast to 1.4 new cases per 100,000 in women. When compared to the rate in 2020, which was 1.7 new cases per 100,000 for both genders per annum, we can clearly see an upward trend. By and large, the growing prevalence of myeloproliferative disorders is fuelling the expansion of the myeloproliferative disorder’s drugs market.

What Segmentation Categories Are Included In The Myeloproliferative Disorders Drugs Market Analysis?

The myeloproliferative disorders drugs market covered in this report is segmented –

1) By Type: Primary Myelofibrosis, Polycythemia Vera (PV), Essential Thrombocythemia (ET), Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES), Systemic Masto cytosis (SM)

2) By Drug Type: JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate, Other Drug Types

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Stores, Drug Stores

Subsegments:

1) By Primary Myelofibrosis: JAK Inhibitors, Immunomodulatory Agents, Supportive Care

2) By Polycythemia Vera (PV): JAK Inhibitors, Hydroxyurea, Phlebotomy, Interferon-alpha

3) By Essential Thrombocythemia (ET): JAK Inhibitors, Hydroxyurea, Anagrelide, Interferon-alpha

4) By Chronic Eosinophilic Leukemia or Hyper Eosinophilic Syndrome (HES): Tyrosine Kinase Inhibitors, Corticosteroids, Interferon-alpha

5) By Systemic Mastocytosis (SM): Tyrosine Kinase Inhibitors, Corticosteroids, Antihistamines, Immunotherapy

What Upcoming Trends Are Expected To Impact The Myeloproliferative Disorders Drugs Market Globally?

In the myeloproliferative disorder drugs marketplace, product innovation is rapidly becoming a predominant trend. Major players in this field are focusing on the development of groundbreaking products as a tactic to consolidate their market standing. For instance, in September 2023, UK-based pharmaceutical and biotech company GSK PLC secured FDA approval for momelotinib for treating primary myelofibrosis, a variant of myeloproliferative disorder (MPD). This new drug is potentially unique, incorporating a specific mechanism that blocks three crucial signaling pathways: JAK 1, JAK 2, and ACVR1. The inhibition of JAK1 and JAK2 can potentially help reduce splenomegaly and constitutional symptoms. Additionally, its direct impact on ACVR1 leads to a reduction in circulating hepcidin levels, which typically elevate in myelofibrosis cases and contribute to anemia.

Who Are The Top-Ranked Companies In The Myeloproliferative Disorders Drugs Market Today?

Major companies operating in the myeloproliferative disorders drugs market include Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Incyte Corporation, Eli Lilly and Co, F Hoffmann-La Roche Ltd., Mylan NV, Fresenius Kabi AG, Hikma Pharmaceuticals plc, GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International Gmbh, Sanofi Aventis Inc., AstraZeneca AB, Apotex Inc, Celgene Co., Gamida Cell Ltd., Geron Co., Promedior Inc., Johnson & Johnson Private Limited, AbbVie Inc., AOP Orphan Pharmaceuticals AG, Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Chemical Pharma Co. Ltd., Eisai Pharmaceuticals India Pvt. Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

How Is Myeloproliferative Disorders Drugs Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the myeloproliferative disorder drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global myeloproliferative disorder drugs market report during the forecast period. The regions covered in the myeloproliferative disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10681&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model